Breaking News, Collaborations & Alliances

Visgenx, Charles River Expand Gene Therapy Manufacturing Alliance

Charles River will manufacture investigational gene therapy treatment for dry age-related macular degeneration.

Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, has extended its contract development and manufacturing collaboration with Charles River Laboratories for VGX-0111, a gene therapy being developed by Visgenx for dry age-related macular degeneration (AMD). Following Visgenx’s Type B pre-IND meeting with the FDA in the summer of 2023, Charles River will begin manufacturing materials for VGX-0111 with the goal of initiating a cli...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters